Get the Stockscreener App
13.30
0.61%
0.08
After Hours:
13.26
-0.04
-0.30%
Hutchmed China Limited Adr stock is traded at $13.30, with a volume of 17,244.
It is up +0.61% in the last 24 hours and down -13.75% over the past month.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
See More
Previous Close:
$13.22
Open:
$13.24
24h Volume:
17,244
Relative Volume:
0.57
Market Cap:
$2.29B
Revenue:
$549.97M
Net Income/Loss:
$458.86M
P/E Ratio:
5.0694
EPS:
2.6236
Net Cash Flow:
$-89.06M
1W Performance:
-2.13%
1M Performance:
-13.75%
6M Performance:
-14.58%
1Y Performance:
-12.04%
1-Day Range:
$13.16
$13.31
1-Week Range:
$12.82
$13.58
52-Week Range:
$12.82
$19.50
Hutchmed China Limited Adr Stock (HCM) Company Profile
Compare HCM vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCM
Hutchmed China Limited Adr
|
13.30 | 2.27B | 549.97M | 458.86M | -89.06M | 2.6236 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-22-25 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| May-13-25 | Downgrade | HSBC Securities | Buy → Hold |
| Nov-24-23 | Upgrade | Deutsche Bank | Hold → Buy |
| May-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Aug-03-21 | Initiated | Jefferies | Buy |
| Oct-02-20 | Initiated | Deutsche Bank | Buy |
| Mar-13-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-20-20 | Initiated | Goldman | Buy |
| Nov-19-19 | Initiated | CLSA | Buy |
| Oct-23-19 | Reiterated | BofA/Merrill | Buy |
| Jul-05-19 | Initiated | Macquarie | Outperform |
View All
Hutchmed China Limited Adr Stock (HCM) Latest News
HUTCHMED (NASDAQ:HCM) Hits New 52-Week LowWhat's Next? - MarketBeat
HUTCHMED (Nasdaq: HCM) reports 872,335,120 voting shares - Stock Titan
HUTCHMED (00013.HK) Sovleplenib NDA Accepted and Granted Priority Review - AASTOCKS.com
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
HUTCHMED (Nasdaq: HCM) gains China priority review and breakthrough status for sovleplenib - Stock Titan
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference - Yahoo Finance
HUTCHMED (NASDAQ:HCM) Shares Gap DownHere's Why - MarketBeat
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on April 28, 2026 - The Manila Times
Hutchmed China (NASDAQ:HCM) Gains Attention Amid Healthcare Momentum - Kalkine Media
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Rating of "Hold" by Analysts - MarketBeat
Revenue per share of HUTCHMED (China) Limited Sponsored ADR – FWB:H7T1 - TradingView — Track All Markets
HCM Stock Price, Quote & Chart | HUTCHMED CHINA-ADR (NASDAQ:HCM) - ChartMill
HUTCHMED (HCM) showcases ATTC and surufatinib study data at AACR 2026 - Stock Titan
HUTCHMED (HCM) plans 2026 AGM, 10% buyback mandate and 5% option pool - Stock Titan
HUTCHMED To Present Data at American Association of Cancer Research Annual Meeting 2026 - AASTOCKS.com
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026 - GlobeNewswire
HUTCHMED (LON:HCM) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell? - Defense World
Takeda Pharmaceutical Company Limited (TAK) stock price, news, quote and history - Yahoo Finance Singapore
Zai Lab Limited (ZLAB) stock price, news, quote and history - uk.finance.yahoo.com
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo Finance
Short Interest in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Decreases By 13.7% - MarketBeat
HUTCHMED (NASDAQ:HCM) Shares Gap UpTime to Buy? - MarketBeat
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
HUTCHMED (NASDAQ:HCM) Stock Price Crosses Below 50-Day Moving AverageHere's Why - MarketBeat
HUTCHMED (Nasdaq: HCM) launches registrational Phase III HMPL-760 lymphoma trial in China - Stock Titan
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China - GlobeNewswire Inc.
HUTCHMED (HCM) vests 19,913 LTIP shares for CEO Dr. Weiguo Su - Stock Titan
HUTCHMED (China) Limited Sponsored ADR $HCM Stake Trimmed by Schroder Investment Management Group - MarketBeat
HUTCHMED (LON:HCM) Share Price Crosses Below 200-Day Moving Average – Time to Sell? - Defense World
HUTCHMED (HCM) vests 726,317 LTIP shares to CEO and CFO - Stock Titan
TAZVERIK cancer drug withdrawn; HUTCHMED (HCM) ends China trials - Stock Titan
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China - ChartMill
CLSA Cuts TP of HUTCHMED (00013.HK) to HKD30.4; Rating Outperform - AASTOCKS.com
Intended Retirement of Independent Non-executive Director and changes of composition of board committees - ChartMill
HUTCHMED (NASDAQ: HCM) plans INED retirement, reshapes board roles - Stock Titan
HUTCHMED H2 Earnings Call Highlights - Yahoo Finance
Food & Life Companies (3563.JP) Plunges 14% Following Alleged Parasite Egg Discovery at Beijing's Sushiro - AASTOCKS.com
[6-K] HUTCHMED (China) Ltd Current Report (Foreign Issuer) | HCM SEC FilingForm 6-K - Stock Titan
HUTCHMED Reports 2025 Full Year Results and Business Updates - GlobeNewswire
HUTCHMED (LON:HCM) Share Price Crosses Below 200-Day Moving Average – What’s Next? - Defense World
Brokerages Set QCR Holdings, Inc. (NASDAQ:QCRH) PT at $102.25 - Defense World
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors - GlobeNewswire
HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Analysts - MarketBeat
HUTCHMED (NASDAQ:HCM) Stock Crosses Below 50 Day Moving AverageHere's What Happened - MarketBeat
JPMorgan Chase & Co. Has $729.86 Million Stock Holdings in iShares ESG Aware MSCI EAFE ETF $ESGD - Defense World
Glenview Trust Co Raises Stock Position in Vanguard Intermediate-Term Corporate Bond ETF $VCIT - Defense World
HUTCHMED (NASDAQ:HCM) Shares Pass Above Fifty Day Moving AverageHere's Why - MarketBeat
UOB Kay Hian Favors ALI HEALTH, PA GOODDOCTOR; AI Innovation & National Policies Drive CN Internet Healthcare Sector - AASTOCKS.com
Labcorp Holdings Inc. $LH Stake Lessened by Jensen Investment Management Inc. - Defense World
Kayne Anderson Energy Infrastructure Fund (NYSE:KYN) Share Price Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World
Hutchmed China Limited Adr Stock (HCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):